Profil
Sandford Sommer is currently the President & Chief Operating Officer at Ligand UK Ltd.
He previously worked as the Director at UK Colombia Trade and as the President-Colombia operations at AstraZeneca PLC.
Postes actifs de Sandford Sommer
| Sociétés | Poste | Début |
|---|---|---|
| VERNALIS | President | 01/05/2016 |
Anciens postes connus de Sandford Sommer
| Sociétés | Poste | Fin |
|---|---|---|
| UK Colombia Trade | Director/Board Member | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
| UK Colombia Trade |
